Super User, Author at BioHealth Innovation

News

Novavax to Provide 40 Million Doses of Its COVID-19 Vaccine Candidate to Australia | The Motley Fool

Novavax (NASDAQ:NVAX) announced on Wednesday that it has reached an agreement to provide the Australian government with 40 million doses of…

Super UserNovember 8, 2020

News

Novavax Announces Facility Expansion to Support Global Vaccine Development | Novavax Inc. – IR Site

GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious…

Super UserNovember 2, 2020

BHI Weekly News Archives

429th Edition, October 28, 2020

BioHealth Innovation If you are having trouble viewing this email, please click here October 28, 2020 FOUNDING MEMBER OF NexImmune…

Super UserNovember 2, 2020

News

What Floreo’s expansion into ADHD means for the autism-focused virtual reality startup – Washington Business Journal

Through a partnership with NIH, D.C. virtual reality startup Floreo is expanding from autism spectrum disorder to attention deficit hyperactivity…

Super UserNovember 2, 2020

JAAN BIOTHERAPEUTICS LLC My WordPress Blog

News

Jaan Biotherapeutics Awarded NIH Grant to Advance Cardiac Muscle Regeneration Therapy – MarketWatch

Sep 05, 2020 (IssueWire via COMTEX) -- San Diego, Sep 5, 2020 (Issuewire.com) - Jaan Biotherapeutics ("JBT"), announced that it…

Super UserNovember 2, 2020

News

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma :: Rexahn Pharmaceuticals, Inc. (REXN)

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting…

Super UserNovember 2, 2020

News

Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease | Business Wire

GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received…

Super UserNovember 2, 2020

News

Emmes Employees Co-Author COVID-19 Vaccine Report for the New England Journal of Medicine | BioSpace

Three Emmes employees were among the co-authors of the recent report, "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older…

Super UserNovember 2, 2020

Cancer is Curable Know Earlier Take Action Together Thrive Detect

News

JHU Spinout Thrive Earlier Detection Lands up to $2.15 Billion in Acquisition by Exact Sciences · BioBuzz

MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company…

Super UserNovember 2, 2020

News

REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG | REGENXBIO Inc.

ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives…

Super UserNovember 2, 2020

Super User

Novavax to Provide 40 Million Doses of Its COVID-19 Vaccine Candidate to Australia | The Motley Fool

Novavax Announces Facility Expansion to Support Global Vaccine Development | Novavax Inc. – IR Site

429th Edition, October 28, 2020

What Floreo’s expansion into ADHD means for the autism-focused virtual reality startup – Washington Business Journal

Jaan Biotherapeutics Awarded NIH Grant to Advance Cardiac Muscle Regeneration Therapy – MarketWatch

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma :: Rexahn Pharmaceuticals, Inc. (REXN)

Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease | Business Wire

Emmes Employees Co-Author COVID-19 Vaccine Report for the New England Journal of Medicine | BioSpace

JHU Spinout Thrive Earlier Detection Lands up to $2.15 Billion in Acquisition by Exact Sciences · BioBuzz

REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG | REGENXBIO Inc.

About BioHealth Innovation

Contact

Connect